DF8100 / Dragonfly Therap, Merck (MSD) - LARVOL DELTA

GOLM1 is related to the inflammatory/immune nature of uveal melanoma and acts as a promising indicator for prognosis and immunotherapy response. (PubMed, Front Genet) - "Moreover, tumor tissue sections from 23 UVM patients were collected and stained for GOLM1 (1:300; cat# DF8100, Affinity Biosciences), PD-L1 (1:250; cat# ab213524, Abcam), PD-1 (1:100; cat# ab52587, Abcam), CTLA-4 (1:300; cat# DF6793, Affinity Biosciences), and IFN-γ (1:300; cat# DF6045, Affinity Biosciences)...Gene pattern and SubMap analyses confirmed the indicator role of GOLM1 in predicting immunotherapy response in UVM. Taken together, GOLM1 is a novel prognostic marker, and it can be employed to predict the overall survival outcomes and treatment responses of anti-PD-1/PD-L1 and anti-CTLA4 therapies for UVM patients."

IO biomarker • Journal • Eye Cancer • Immunology • Inflammation • Melanoma • Oncology • Solid Tumor • Uveal Melanoma • IFNG